467 related articles for article (PubMed ID: 31731192)
1. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
2. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
3. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
4. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
Ipsen DH; Lykkesfeldt J; Tveden-Nyborg P
Cell Mol Life Sci; 2018 Sep; 75(18):3313-3327. PubMed ID: 29936596
[TBL] [Abstract][Full Text] [Related]
6. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
7. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
8. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
Wang J; Yang N; Xu Y
Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
[TBL] [Abstract][Full Text] [Related]
9. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis.
Xu J; Li Y; Chen WD; Xu Y; Yin L; Ge X; Jadhav K; Adorini L; Zhang Y
Hepatology; 2014 May; 59(5):1761-1771. PubMed ID: 24038130
[TBL] [Abstract][Full Text] [Related]
10. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
Zhou S; You H; Qiu S; Yu D; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
Biomed Pharmacother; 2022 Oct; 154():113577. PubMed ID: 35988420
[TBL] [Abstract][Full Text] [Related]
11. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
12. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
13. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.
Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W
Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572
[TBL] [Abstract][Full Text] [Related]
14. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
Xu JY; Li ZP; Zhang L; Ji G
World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
[TBL] [Abstract][Full Text] [Related]
16. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease.
Chrysavgis L; Giannakodimos I; Chatzigeorgiou A; Tziomalos K; Papatheodoridis G; Cholongitas E
Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):835-849. PubMed ID: 36124827
[TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.
Xiong X; Wang X; Lu Y; Wang E; Zhang Z; Yang J; Zhang H; Li X
J Hepatol; 2014 Apr; 60(4):847-54. PubMed ID: 24333182
[TBL] [Abstract][Full Text] [Related]
18. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
19.
Shi Y; Pizzini J; Wang H; Das F; Abdul Azees PA; Ghosh Choudhury G; Barnes JL; Zang M; Weintraub ST; Yeh CK; Katz MS; Kamat A
Am J Physiol Endocrinol Metab; 2021 Jul; 321(1):E90-E104. PubMed ID: 34029162
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease.
Xu S; Kong L; Li L; Wang C; Gu J; Luo H; Meng Q
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166930. PubMed ID: 37918680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]